-
1
-
-
34548304886
-
European study on orthopaedic status of haemophilia patients with inhibitors
-
Morfini M, Haya S, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-12.
-
(2007)
Haemophilia
, vol.13
, pp. 606-612
-
-
Morfini, M.1
Haya, S.2
Tagariello, G.3
-
2
-
-
79951903554
-
Inhibitors in Haemophilia: A Primer
-
Accessible from the World Federation of Hemophilia at Accessed June 2, 2010.
-
Di Michele DM. Inhibitors in Haemophilia: A Primer. 2008. Accessible from the World Federation of Hemophilia at Accessed June 2, 2010.
-
(2008)
-
-
Di Michele, D.M.1
-
3
-
-
62149132517
-
Haemophilia care in children--benefits of early prophylaxis for inhibitor prevention
-
Mancuso ME, Graca L, Auerswald G, Santagostino E. Haemophilia care in children--benefits of early prophylaxis for inhibitor prevention. Haemophilia 2009; 15(Suppl. 1): 8-14.
-
(2009)
Haemophilia
, vol.15
, Issue.SUPPL. 1
, pp. 8-14
-
-
Mancuso, M.E.1
Graca, L.2
Auerswald, G.3
Santagostino, E.4
-
4
-
-
9144271883
-
The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99
-
Darby SC, Keeling DM, Spooner RJ et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2: 1047-54.
-
(2004)
J Thromb Haemost
, vol.2
, pp. 1047-1054
-
-
Darby, S.C.1
Keeling, D.M.2
Spooner, R.J.3
-
5
-
-
12144290833
-
Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors
-
Soucie JM, Cianfrini C, Janco RL et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004; 103: 2467-73.
-
(2004)
Blood
, vol.103
, pp. 2467-2473
-
-
Soucie, J.M.1
Cianfrini, C.2
Janco, R.L.3
-
6
-
-
33645963126
-
Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors
-
Scalone L, Mantovani LG, Mannucci PM, Gringeri A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006; 12: 154-62.
-
(2006)
Haemophilia
, vol.12
, pp. 154-162
-
-
Scalone, L.1
Mantovani, L.G.2
Mannucci, P.M.3
Gringeri, A.4
-
7
-
-
33645750469
-
Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial
-
Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006; 95: 600-5.
-
(2006)
Thromb Haemost
, vol.95
, pp. 600-605
-
-
Kavakli, K.1
Makris, M.2
Zulfikar, B.3
Erhardtsen, E.4
Abrams, Z.S.5
Kenet, G.6
-
8
-
-
0642372623
-
A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven)
-
Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost 2003; 1: 450-5.
-
(2003)
J Thromb Haemost
, vol.1
, pp. 450-455
-
-
Kenet, G.1
Lubetsky, A.2
Luboshitz, J.3
Martinowitz, U.4
-
9
-
-
0032950164
-
Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention
-
Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol 1999; 104: 22-6.
-
(1999)
Br J Haematol
, vol.104
, pp. 22-26
-
-
Santagostino, E.1
Gringeri, A.2
Mannucci, P.M.3
-
10
-
-
20144389671
-
Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry
-
Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-6.
-
(2005)
Haemophilia
, vol.11
, pp. 100-106
-
-
Parameswaran, R.1
Shapiro, A.D.2
Gill, J.C.3
Kessler, C.M.4
-
11
-
-
0031788226
-
Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor
-
Stewart AJ, Hanley JP, Ludlam CA. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor. Blood Coagul Fibrinolysis 1998; 9(Suppl. 1): S93-5.
-
(1998)
Blood Coagul Fibrinolysis
, vol.9
, Issue.SUPPL. 1
-
-
Stewart, A.J.1
Hanley, J.P.2
Ludlam, C.A.3
-
12
-
-
0031701033
-
Early treatment with recombinant factor VIIa results in greater efficacy with less product
-
Lusher JM. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol Suppl 1998; 63: 7-10.
-
(1998)
Eur J Haematol Suppl
, vol.63
, pp. 7-10
-
-
Lusher, J.M.1
-
13
-
-
41849103412
-
Avoiding the impact of musculoskeletal pain on quality of life in children with hemophilia
-
quiz 9-10.
-
Sherry DD. Avoiding the impact of musculoskeletal pain on quality of life in children with hemophilia. Orthop Nurs 2008; 27: 103-8; quiz 9-10.
-
(2008)
Orthop Nurs
, vol.27
, pp. 103-108
-
-
Sherry, D.D.1
-
14
-
-
53249097439
-
Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors?
-
Rodriguez-Merchan EC, Hedner U, Heijnen L et al. Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors? Haemophilia 2008; 14(Suppl. 6): 68-81.
-
(2008)
Haemophilia
, vol.14
, Issue.SUPPL. 6
, pp. 68-81
-
-
Rodriguez-Merchan, E.C.1
Hedner, U.2
Heijnen, L.3
-
15
-
-
33646686129
-
The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation
-
Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133: 591-605.
-
(2006)
Br J Haematol
, vol.133
, pp. 591-605
-
-
Hay, C.R.1
Brown, S.2
Collins, P.W.3
Keeling, D.M.4
Liesner, R.5
-
16
-
-
79951920694
-
-
World Federation of Hemophilia. Guidelines for the Management of Hemophilia. Accessible from the World Federation of Hemophilia at Accessed June 2, 2010.
-
World Federation of Hemophilia. Guidelines for the Management of Hemophilia. 2005. Accessible from the World Federation of Hemophilia at Accessed June 2, 2010.
-
(2005)
-
-
-
17
-
-
63049090494
-
Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors
-
Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia 2009; 15: 3-10.
-
(2009)
Haemophilia
, vol.15
, pp. 3-10
-
-
Berntorp, E.1
-
18
-
-
34548321383
-
A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation
-
Bysted BV, Scharling B, Moller T, Hansen BL. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation. Haemophilia 2007; 13: 527-32.
-
(2007)
Haemophilia
, vol.13
, pp. 527-532
-
-
Bysted, B.V.1
Scharling, B.2
Moller, T.3
Hansen, B.L.4
-
19
-
-
33947494621
-
Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A
-
Sorensen B, Persson E, Ingerslev J. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A. Br J Haematol 2007; 137: 158-65.
-
(2007)
Br J Haematol
, vol.137
, pp. 158-165
-
-
Sorensen, B.1
Persson, E.2
Ingerslev, J.3
-
20
-
-
17144437423
-
Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors
-
Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
-
(1998)
Thromb Haemost
, vol.80
, pp. 912-918
-
-
Key, N.S.1
Aledort, L.M.2
Beardsley, D.3
-
21
-
-
40349085780
-
Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison
-
Young G, Shafer FE, Rojas P, Seremetis S. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008; 14: 287-94.
-
(2008)
Haemophilia
, vol.14
, pp. 287-294
-
-
Young, G.1
Shafer, F.E.2
Rojas, P.3
Seremetis, S.4
-
22
-
-
0020662181
-
The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors
-
Hilgartner MW, Knatterud GL. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61: 36-40.
-
(1983)
Blood
, vol.61
, pp. 36-40
-
-
Hilgartner, M.W.1
Knatterud, G.L.2
-
23
-
-
33750342991
-
A retrospective postlicensure survey of FEIBA efficacy and safety
-
Dimichele D, Negrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006; 12: 352-62.
-
(2006)
Haemophilia
, vol.12
, pp. 352-362
-
-
Dimichele, D.1
Negrier, C.2
-
24
-
-
0025180213
-
Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group
-
Hilgartner M, Aledort L, Andes A, Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 1990; 30: 626-30.
-
(1990)
Transfusion
, vol.30
, pp. 626-630
-
-
Hilgartner, M.1
Aledort, L.2
Andes, A.3
Gill, J.4
-
25
-
-
0030837755
-
Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity
-
Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77: 1113-9.
-
(1997)
Thromb Haemost
, vol.77
, pp. 1113-1119
-
-
Negrier, C.1
Goudemand, J.2
Sultan, Y.3
Bertrand, M.4
Rothschild, C.5
Lauroua, P.6
-
26
-
-
77953553566
-
The value of early treatment in patients with haemophilia and inhibitors
-
Epub ahead of print)
-
Kavakli K, Yesilipek A, Antmen B et al. The value of early treatment in patients with haemophilia and inhibitors. Haemophilia (Epub ahead of print) 2010.
-
(2010)
Haemophilia
-
-
Kavakli, K.1
Yesilipek, A.2
Antmen, B.3
-
29
-
-
0037327650
-
Management of musculoskeletal complications of hemophilia
-
Rodriguez-Merchan EC. Management of musculoskeletal complications of hemophilia. Semin Thromb Hemost 2003; 29: 87-96.
-
(2003)
Semin Thromb Hemost
, vol.29
, pp. 87-96
-
-
Rodriguez-Merchan, E.C.1
-
30
-
-
27844464439
-
Hemophilia orthopedic management with emphasis on developing countries
-
Rodriguez-Merchan EC, Heim M. Hemophilia orthopedic management with emphasis on developing countries. Semin Thromb Hemost 2005; 31: 518-26.
-
(2005)
Semin Thromb Hemost
, vol.31
, pp. 518-526
-
-
Rodriguez-Merchan, E.C.1
Heim, M.2
-
31
-
-
79951792726
-
The need for speed in the management of haemophilia patients with inhibitors
-
Apr 12 [Epub ahead of print]. DOI:
-
Salek SZ, Benson GM, Elezovic I et al. The need for speed in the management of haemophilia patients with inhibitors. Haemophilia 2010; Apr 12 [Epub ahead of print]. DOI:
-
(2010)
Haemophilia
-
-
Salek, S.Z.1
Benson, G.M.2
Elezovic, I.3
-
32
-
-
0019478825
-
The identification of high-risk elbow hemorrhages in adolescents with severe hemophilia A
-
Aronstam A, Wassef M, Hamad Z, Aston DL. The identification of high-risk elbow hemorrhages in adolescents with severe hemophilia A. J Pediatr 1981; 98: 776-8.
-
(1981)
J Pediatr
, vol.98
, pp. 776-778
-
-
Aronstam, A.1
Wassef, M.2
Hamad, Z.3
Aston, D.L.4
-
33
-
-
63349085503
-
Efficacy of recombinant activated factor VII (rFVIIa) vs. activated prothrombin complex concentrate (aPCC) for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression
-
Treur M, McCracken F, Heeg B et al. Efficacy of recombinant activated factor VII (rFVIIa) vs. activated prothrombin complex concentrate (aPCC) for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression. Haemophilia 2009; 15: 420-36.
-
(2009)
Haemophilia
, vol.15
, pp. 420-436
-
-
Treur, M.1
McCracken, F.2
Heeg, B.3
-
34
-
-
33645573977
-
A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors
-
Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 367-71.
-
(2006)
J Thromb Haemost
, vol.4
, pp. 367-371
-
-
Santagostino, E.1
Mancuso, M.E.2
Rocino, A.3
Mancuso, G.4
Scaraggi, F.5
Mannucci, P.M.6
-
35
-
-
65449145067
-
Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic
-
Salaj P, Brabec P, Penka M et al. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia 2009; 15: 752-9.
-
(2009)
Haemophilia
, vol.15
, pp. 752-759
-
-
Salaj, P.1
Brabec, P.2
Penka, M.3
-
36
-
-
0141928848
-
Modelling the economic impact of recombinant activated factor VII compared to activated prothrombin-complex concentrate in the home treatment of a mild to moderate bleed in adults with inhibitors to clotting factors VIII and IX in the UK
-
Odeyemi I, Guest J. Modelling the economic impact of recombinant activated factor VII compared to activated prothrombin-complex concentrate in the home treatment of a mild to moderate bleed in adults with inhibitors to clotting factors VIII and IX in the UK. J Med Econ 2004; 5: 119-33.
-
(2004)
J Med Econ
, vol.5
, pp. 119-133
-
-
Odeyemi, I.1
Guest, J.2
-
37
-
-
40949147818
-
Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders
-
Croom KF, McCormack PL. Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders. BioDrugs 2008; 22: 121-36.
-
(2008)
BioDrugs
, vol.22
, pp. 121-136
-
-
Croom, K.F.1
McCormack, P.L.2
-
38
-
-
65449161303
-
FEIBA in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre
-
Smejkal P, Brabec P, Matyskova M et al. FEIBA in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre. Haemophilia 2009; 15: 743-51.
-
(2009)
Haemophilia
, vol.15
, pp. 743-751
-
-
Smejkal, P.1
Brabec, P.2
Matyskova, M.3
-
39
-
-
33646126521
-
Pathogenesis of haemophilic arthropathy
-
Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia 2006; 12(Suppl. 3): 117-21.
-
(2006)
Haemophilia
, vol.12
, Issue.SUPPL. 3
, pp. 117-121
-
-
Roosendaal, G.1
Lafeber, F.P.2
-
40
-
-
53249090238
-
Haemophilic arthropathy: the importance of the earliest haemarthroses and consequences for treatment
-
Roosendaal G, Jansen NW, Schutgens R, Lafeber FP. Haemophilic arthropathy: the importance of the earliest haemarthroses and consequences for treatment. Haemophilia 2008; 14(Suppl. 6): 4-10.
-
(2008)
Haemophilia
, vol.14
, Issue.SUPPL. 6
, pp. 4-10
-
-
Roosendaal, G.1
Jansen, N.W.2
Schutgens, R.3
Lafeber, F.P.4
-
41
-
-
65449121410
-
IL-1β, IL-6, KC and MCP-1 are elevated in synovial fluid from haemophilic mice with experimentally induced haemarthrosis
-
Øvlisen K, Kristensen A, Jensen A, Tranholm M. IL-1β, IL-6, KC and MCP-1 are elevated in synovial fluid from haemophilic mice with experimentally induced haemarthrosis. Haemophilia 2009; 15: 802-10.
-
(2009)
Haemophilia
, vol.15
, pp. 802-810
-
-
Øvlisen, K.1
Kristensen, A.2
Jensen, A.3
Tranholm, M.4
-
42
-
-
70449562279
-
Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens
-
Berntorp E. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens. Haemophilia 2009; 15: 1219-27.
-
(2009)
Haemophilia
, vol.15
, pp. 1219-1227
-
-
Berntorp, E.1
-
43
-
-
44249113317
-
Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors
-
Fischer K, Valentino L, Ljung R, Blanchette V. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors. Haemophilia 2008; 14(Suppl. 3): 196-201.
-
(2008)
Haemophilia
, vol.14
, Issue.SUPPL. 3
, pp. 196-201
-
-
Fischer, K.1
Valentino, L.2
Ljung, R.3
Blanchette, V.4
-
44
-
-
53249113250
-
Experiences in the prevention of arthropathy in haemophila patients with inhibitors
-
Jimenez-Yuste V, Rodriguez-Merchan EC, Alvarez MT, Quintana M, Martin-Salces M, Hernandez-Navarro F. Experiences in the prevention of arthropathy in haemophila patients with inhibitors. Haemophilia 2008; 14(Suppl. 6): 28-35.
-
(2008)
Haemophilia
, vol.14
, Issue.SUPPL. 6
, pp. 28-35
-
-
Jimenez-Yuste, V.1
Rodriguez-Merchan, E.C.2
Alvarez, M.T.3
Quintana, M.4
Martin-Salces, M.5
Hernandez-Navarro, F.6
-
45
-
-
77950208649
-
Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors
-
Valentino LA. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors. Haemophilia 2010; 16: 263-71.
-
(2010)
Haemophilia
, vol.16
, pp. 263-271
-
-
Valentino, L.A.1
-
46
-
-
34548096392
-
Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors
-
Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
-
(2007)
J Thromb Haemost
, vol.5
, pp. 1904-1913
-
-
Konkle, B.A.1
Ebbesen, L.S.2
Erhardtsen, E.3
-
47
-
-
33748047802
-
Knowledge, attitudes, and behaviors of youths in the US hemophilia population: results of a national survey
-
Nazzaro AM, Owens S, Hoots WK, Larson KL. Knowledge, attitudes, and behaviors of youths in the US hemophilia population: results of a national survey. Am J Public Health 2006; 96: 1618-22.
-
(2006)
Am J Public Health
, vol.96
, pp. 1618-1622
-
-
Nazzaro, A.M.1
Owens, S.2
Hoots, W.K.3
Larson, K.L.4
-
48
-
-
79951923841
-
Knowledge and behaviors regarding complication and prevention of patients with hemophila in Korea
-
P-S-032.
-
Choi K, Kim M, Lee K. Knowledge and behaviors regarding complication and prevention of patients with hemophila in Korea. J Thromb Haemost 2007; 5: P-S-032.
-
(2007)
J Thromb Haemost
, vol.5
-
-
Choi, K.1
Kim, M.2
Lee, K.3
-
49
-
-
65449155974
-
Home treatment with bypassing products in inhibitor patients: a 7.5-year experience
-
Holme PA, Glomstein A, Gronhaug S, Tjonnfjord GE. Home treatment with bypassing products in inhibitor patients: a 7.5-year experience. Haemophilia 2009; 15: 727-32.
-
(2009)
Haemophilia
, vol.15
, pp. 727-732
-
-
Holme, P.A.1
Glomstein, A.2
Gronhaug, S.3
Tjonnfjord, G.E.4
-
50
-
-
79951778898
-
Implementation of on-demand treatment protocol in adult patients with severe haemophilia by an emerging program for comprehensive care of haemophilia: preliminary results. Poster 25 PO 15
-
Zuniga P, Morales J, Reyes I et al. Implementation of on-demand treatment protocol in adult patients with severe haemophilia by an emerging program for comprehensive care of haemophilia: preliminary results. Poster 25 PO 15. Haemophilia 2008; 14: 121-58.
-
(2008)
Haemophilia
, vol.14
, pp. 121-158
-
-
Zuniga, P.1
Morales, J.2
Reyes, I.3
-
52
-
-
63349090774
-
Patients', physicians', and pharmacists' preferences towards coagulation factor concentrates to treat haemophilia with inhibitors: results from the COHIBA Study
-
Scalone L, Mantovani LG, Borghetti F, Von Mackensen S, Gringeri A. Patients', physicians', and pharmacists' preferences towards coagulation factor concentrates to treat haemophilia with inhibitors: results from the COHIBA Study. Haemophilia 2009; 15: 473-86.
-
(2009)
Haemophilia
, vol.15
, pp. 473-486
-
-
Scalone, L.1
Mantovani, L.G.2
Borghetti, F.3
Von Mackensen, S.4
Gringeri, A.5
-
53
-
-
76149100844
-
Enhanced and prolonged efficacy of a novel recombinant FVIIa variant (BAY86-6150) for acute and prophylactic treatments in hemophilia A (HemA) mice
-
Abstract OC-WE-057.
-
Liu T, Zhang X, Pan J et al. Enhanced and prolonged efficacy of a novel recombinant FVIIa variant (BAY86-6150) for acute and prophylactic treatments in hemophilia A (HemA) mice. J Thromb Haemost 2009; 7(Suppl. 2): 222; Abstract OC-WE-057.
-
(2009)
J Thromb Haemost
, vol.7
, Issue.SUPPL. 2
, pp. 222
-
-
Liu, T.1
Zhang, X.2
Pan, J.3
-
54
-
-
55549105470
-
Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives
-
Stennicke HR, Ostergaard H, Bayer RJ et al. Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives. Thromb Haemost 2008; 100: 920-8.
-
(2008)
Thromb Haemost
, vol.100
, pp. 920-928
-
-
Stennicke, H.R.1
Ostergaard, H.2
Bayer, R.J.3
-
55
-
-
53449102958
-
Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa
-
Schulte S. Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa. Thromb Res 2008; 122(Suppl. 4): S14-9.
-
(2008)
Thromb Res
, vol.122
, Issue.SUPPL. 4
-
-
Schulte, S.1
-
56
-
-
79951894292
-
Functional characterization of a new recombinant FVIII (N8)
-
Abstract PP-WE-589.
-
Kjalke M, Christiansen MS, Balling KW et al. Functional characterization of a new recombinant FVIII (N8). J Thromb Haemost 2009; 7(Suppl. 2): 826; Abstract PP-WE-589.
-
(2009)
J Thromb Haemost
, vol.7
, Issue.SUPPL. 2
, pp. 826
-
-
Kjalke, M.1
Christiansen, M.S.2
Balling, K.W.3
-
57
-
-
79951911123
-
A phase II open-label study evaluating the hemostatic activity, pharmacokinetics and safety of recombinant porcine factor VIII (OBI-1) in hemophilia A patients with inhibitors directed against human FVII
-
Mahlangu J, Andreeva T, MacFarlane D et al. A phase II open-label study evaluating the hemostatic activity, pharmacokinetics and safety of recombinant porcine factor VIII (OBI-1) in hemophilia A patients with inhibitors directed against human FVII. Haemophilia 2008; 14: 15.
-
(2008)
Haemophilia
, vol.14
, pp. 15
-
-
Mahlangu, J.1
Andreeva, T.2
MacFarlane, D.3
-
58
-
-
34248551364
-
Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience
-
Schneiderman J, Rubin E, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007; 13: 244-8.
-
(2007)
Haemophilia
, vol.13
, pp. 244-248
-
-
Schneiderman, J.1
Rubin, E.2
Nugent, D.J.3
Young, G.4
|